Blog Archives

Therapies that promote progressive multifocal leukoencephalopathy (PML)

August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus,

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Fingolimod (Gilenya): Warning about rare cases of progressive multifocal leukoencephalopathy (PML)

August 06, 1015 – The American Food and Drug Administration (FDA) has just issued a warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Fingolimod (Gilenya) for multiple sclerosis (MS).

Read more ›

Tags: , , , , , , , ,

Ofatumumab (Arzerra) approved for recurrent or progressive chronic lymphocytic leukemia (CLL)

January 20, 2016 – The American Food and Drug Administration (FDA) just approved Ofatumumab (Arzerra)  Injection for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). 

Read more ›

Tags: , , , , , , , , ,

Theragenomic medicine: First case of fumarate-linked progressive multifocal leukoencephalopathy (PML) in nonlymphopenic patient

April 11, 2015 – Dutch clinicians report what they believe is the first case of progressive multifocal leukoencephalopathy (PML) after treatment with compounded dimethyl fumarate (DMF) in a patient without severe lymphocytopenia. This situation was “previously thought to be unlikely,” Dennis Nieuwkamp,

Read more ›

Tags: , , , ,

First Case of Progressive Multifocal Leukoencephalopathy (PML) in a Patient Treated with Dimethyl Fumarate [Tecfidera]

November 7, 1014 –  This report originates from the meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) on 3-6 November 2014 at EMA.

At this meeting, the PRAC took note and advised on informing about first case of PML in a patient treated with Tecfidera.

Read more ›

Tags: , , , ,

Vedolizumab [Entyvio]: FDA approves Entyvio to treat ulcerative colitis and Crohn’s disease

May 22, 2014 – The U.S. Food and Drug Administration  approved  on May 20, 2014, Entyvio (vedolizumab) injection to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn‘s disease. Entyvio is approved to treat those conditions when one or more standard therapies (corticosteroids,

Read more ›

Tags: , , , , ,

Drug Safety Communication on Brentuximab Vedotin [Adcetris] – Progressive Multifocal Leukoencephalopathy (PML) and Pulmonary Toxicity

January 16, 2012 – The American Food and Drug Administration ( FDA) released on January 13, 2012 the following drug safety communication:

_________________

ISSUE: FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death,

Read more ›

Tags: , , , ,

Belatacept [Nulojix]: Increased Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML)

July 7, 2011 – Bristol-Myers Squibb (BMS) today informed healthcare professionals about a REMS (Risk Evaluation and Mitigation Strategy) that is required for Belatacept [Nulojix] to ensure that the benefits of Belatacept [Nulojix] outweigh the risks of Post-Transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML), both of which can be fatal.

Read more ›

Tags: , , ,

When is a drug too risky to stay on the market?

July 04, 2010 – The arthritis pill Rofecoxib [Vioxx] was withdrawn from the market but menopause hormones were not, even though both were tied to heart risks. A multiple sclerosis medicine was pulled and later allowed back on. So, when is a drug too risky to stay on the market?

Read more ›

Tags: , , , , ,

Rituximab [Rituxan] – Progressive Multifocal Leukoencephalopathy [PML]

October 23, 2009 – Today, Genentech and FDA notified healthcare professionals about a third case of progressive multifocal leukoencephalopathy [PML], the first case of PML in a patient with rheumatoid arthritis [RA] treated with Rituximab [Rituxan] who has not previously received treatment with a TNF antagonist.

Read more ›

Tags: ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Single-cell RNA sequencing reveals details about individual cells in pancreatic tumors September 30, 2020
    Led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and by HonorHealth Research and Innovation Institute, an international team of researchers have described in detail the individual cells that comprise the pancreatic cancer microenvironment, a critical step in devising new treatment options for patients with this aggressive and difficult-to-treat disease.
  • Study: Neanderthal genes are a liability for COVID patients September 30, 2020
    Scientists say genes that some people have inherited from their Neanderthal ancestors may increase their likelihood of suffering severe forms of COVID-19.
  • Concealed cardiomyopathies revealed in cardiac arrest survivors September 30, 2020
    Centenary Institute researchers have discovered that genetic testing can identify "concealed cardiomyopathies" in nearly a quarter of sudden cardiac arrest (SCA) survivors who seem to have a normal heart.
  • Genetic risk of developing obesity is driven by variants that affect the brain September 29, 2020
    Some people are at higher risk of developing obesity because they possess genetic variants that affect how the brain processes sensory information and regulates feeding and behavior. The findings from scientists at the University of Copenhagen support a growing body of evidence that obesity is a disease whose roots are in the brain.
  • Inflammatory gene provides clue to obesity risk September 29, 2020
    A gene that helps to control inflammation increases the risk of obesity and could be turned off in mice to stop weight gain, a study from The University of Queensland has found.
  • Single-cell RNA sequencing reveals details about individual cells in pancreatic tumors September 30, 2020
    Led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and by HonorHealth Research and Innovation Institute, an international team of researchers have described in detail the individual cells that comprise the pancreatic cancer microenvironment, a critical step in devising new treatment options for patients with this aggressive and difficult-to-treat disease. […]
  • Ocean warming and acidification effects on calcareous phytoplankton communities September 30, 2020
    A new study led by researchers from the Institute of Environmental Science and Technology of the Universitat Autònoma de Barcelona (ICTA-UAB) warns that the negative effects of rapid ocean warming on planktonic communities will be exacerbated by ocean acidification.
  • Videos most effective in communicating with parents about secondhand smoke risks September 30, 2020
    The best way to communicate with parent smokers about the risks of secondhand smoke to their children is to use videos depicting the risks, as well as solutions to reduce those risks.
  • Antipsychotics for treating adult depression linked with higher mortality September 30, 2020
    Rutgers researchers, together with colleagues at Columbia University, have reported an increased mortality risk in adults with depression who initiated augmentation with newer antipsychotic medications compared to a control group that initiated augmentation with a second antidepressant.
  • Is it time to reframe the assisted dying debate? September 30, 2020
    Several articles published by The BMJ today explore the debate around assisted dying, in which, subject to safeguards, terminally ill people who are near to death, suffering, and of sound mind, could ask for drugs that they would take to end their lives.
Top